Skip to content

A Randomized-Controlled Trial to Increase the Uptake of LARCs in Cameroon

A Sequential and Adaptive Experiment to Increase the Uptake of Long-acting Reversible Contraceptives in Cameroon

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT03733678
Acronym
HGOPY
Enrollment
2500
Registered
2018-11-07
Start date
2021-03-23
Completion date
2024-12-31
Last updated
2025-05-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Contraception, Contraception Behavior, Contraceptive Method Switching, Contraceptive Usage

Keywords

adolescent sexual and reproductive health, maternal mortality, teen pregnancy, LARCs, family planning counseling

Brief summary

Cameroon exhibits a high and non-decreasing level of maternal mortality (roughly 600 per 100,000 live births), partially related to its relatively high total fertility rate (roughly 4.6). Survey evidence furthermore suggests that a significant fraction of these pregnancies is unwanted or considered mistimed by the mother, especially among females aged 15-19. Despite this, the rate of utilization of family planning (FP) is low: e.g. only 48% of sexually active unmarried women use any form of (modern) contraception, or MC, and even then, it is primarily condoms. The use of LARCs (long-acting reversible contraceptives, i.e. the IUD and implant) is less than 1% according to the most recent Demographic Health Survey. The study investigators propose to use an integrated behavioral science approach to increase the take-up of both SARCs (short-acting reversible contraceptives, i.e. the pill and injectable) and especially LARCs among reproductive-age females in Cameroon, including adolescents who may be unmarried and/or nulliparous. In addition to decreasing maternal mortality and undesired pregnancies, indirect effects for the community will include: increased welfare from reduced side effects that arise due to current one-size-fits-all FP counseling; healthier children due to improved birth spacing; and increased human capital formation both for children and for young (often school-aged) potential mothers. The study investigators propose to conduct the study at HGOPY for a duration of 12 months. The study investigators will provide tablets to each of five nurses that conduct FP counseling to participants at the hospital. The tablets contain a counseling app (or decision-support tool or a job-aid) that was jointly developed by professionals from HGOPY, the World Bank, and the Ministry of Health. The study investigators propose an individually-randomized experiment, where the participants will be offered randomly varying discounts for the modern contraceptive methods they wish to adopt. The study investigators also propose to experiment with certain aspects of the app to improve its effectiveness - both for the participant and for the nurse. More details on the experimental design are provided below.

Interventions

BEHAVIORALPrice discounts for SARCs

SARCs are offered free to the client

BEHAVIORALPrice discounts for LARCs

LARCs are offered at lower prices to the client

BEHAVIORALSequential vs. simultaneous recommendations

Top ranked methods are presented to the client sequentially or simultaneously

Sponsors

Stanford University
CollaboratorOTHER
George Washington University
CollaboratorOTHER
University of Exeter
CollaboratorOTHER
University of California, San Diego
CollaboratorOTHER
Yaounde Gynecology, Obstetrics and Pediatrics Hospital
CollaboratorUNKNOWN
World Bank
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
SEQUENTIAL
Primary purpose
HEALTH_SERVICES_RESEARCH
Masking
SINGLE (Subject)

Masking description

Participants are masked in some interventions related to the workings of the tablet-based decision-support tool, but not to the price discounts they receive for the contraceptive methods.

Intervention model description

The study independently experiments with two aspects of the health provider-client relationship: 1. First, a tablet-based counseling app that is used by the provider gives random discounts to clients - separately for LARCs and SARCs. 2. Second, the tablet-based app presents recommendations to the client sequentially (i.e. the top-ranked method, followed by the next one if that recommendation is declined by the client, etc.) vs. simultaneously (i.e. presenting the top recommendations to the client all at once and asking her to choose which one to discuss further).

Eligibility

Sex/Gender
FEMALE
Age
10 Years to 49 Years
Healthy volunteers
Yes

Inclusion criteria

* Female * Ages 10-49 * Presenting at HGOPY seeking FP counseling/services * HGOPY clients referred to the family planning unit for consultation

Exclusion criteria

\* No

Design outcomes

Primary

MeasureTime frameDescription
The client adopted a LARC1-dayusing data from the counseling sessions
The client adopted a modern contraceptive method (LARC or SARC)1-dayusing data from the counseling sessions

Secondary

MeasureTime frameDescription
Did the health provider give information about contraceptive methods that was easy to understand during the counseling session?2-weeksSelf-reported indicator variable using follow-up surveys two weeks after counseling session
Client satisfaction with adopted contraceptive method2-week and 16-week measurementsusing 2-week and 16-week follow-up surveys
Was the client treated with respect by the provider during the counseling session?2-weeksSelf-reported indicator variable using follow-up surveys two weeks after counseling session
Percentage of participants with unintended pregnancy within the time frame16-week and 52-week measurementsusing 16-week and 52-week follow-up surveys
Discontinuation of adopted contraceptive method2-week, 16-week, and 52-week measurementsusing 2-week, 16-week, and 52-week follow-up surveys
Did the client trust the provider during the counseling session?2-weeksSelf-reported indicator variable using follow-up surveys two weeks after counseling session

Countries

Cameroon

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026